CTLA4 and hepatocellular carcinoma: In a recent study, systemic therapy of patients with chronic hepatitis C infection and HCC with the CTLA-4 inhibitory antibody tremelimumab was both safe and efficacious resulting in partial responses and high disease control rates6.